Penn Pharma wins Best in Class for Innovation
Pharmaceutical manufacturer Penn Pharma received a prestigious accolade at the annual CMO Leadership Awards, in New York this month winning Best in Class for Innovation
In 2013, Penn Pharma won three of the five possible CMO Leadership Awards for Innovation, Productivity and Regulatory and this year were entered into the newly introduced Best in Class Award for Innovation. Penn became eligible for this new award after receiving the highest perception score in this important category.
The awards, set up by Life Science Leader, were developed in response to the difficulties their readers encountered when vetting CMO partners. It recognises companies who achieve the top 20 percentile in perception scores.
US Business Development Executive, Mike Miller attended the event said: “It was an honour to be invited to participate in an evening that recognises superior performance in the CMO industry.”
Penn Pharma Chief Executive, Richard Yarwood added: “We pride ourselves on our commitment to innovation and to be recognised as Best in Class in this category proves that our hard work is being recognised.
"To be entered into these awards based on customer feedback is a great achievement and knowing that we are recognised for our innovation only strengthens our desire to continue to lead new developments in our industry sector.”
Vice President of Publishing, Life Science Leader, Jon Howland said: "The CMO Leadership Awards are a data driven award taking input from over 10,000 customers of CMO services. The Industry Choice Award recognizes the companies that these customers view as being the best in the respective categories. We congratulate the employees of Penn Pharma for being recognised with that honour."
Penn Pharma, based in Tredegar in Blaenau Gwent, South Wales delivers integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.